The Witch Hunt: After Valeant, Beware Complex Companies

Convergex’s Nicholas Colas contends that the questions surrounding Valeant Pharmaceuticals International’s (VRX) accounting–it was compared to Enron earlier this week–”will morph into a witch hunt for any company where the books aren’t crystal clear.” He explains why: lucas jackson/Reuters The largest and most notable rotation, and one that we’ve seen on our own institutional client […]